BeiGene

BeiGene is one of the few oncology-focused biopharmaceutical companies to have built genuinely global commercial and clinical operations from a foundation in China, becoming a Nasdaq- and Hong Kong-listed organisation with a presence spanning more than 45 countries. Founded in 2010 and headquartered in Beijing, with major operations hubs in Cambridge (Massachusetts), Basel, and across the Asia-Pacific region, the company has grown into one of the largest clinical-stage and commercial oncology enterprises in the world by pipeline breadth.

Oncology Pipeline & Approved Medicines

The company's most widely recognised asset is zanubrutinib, a BTK inhibitor marketed as Brukinsa, which has received regulatory approval in the United States, European Union, China, and numerous other markets for haematological malignancies including chronic lymphocytic leukaemia, Waldenström's macroglobulinaemia, and mantle cell lymphoma. Brukinsa is designed as a next-generation BTK inhibitor with a selectivity and dosing profile intended to address limitations observed in earlier compounds in its class. Beyond Brukinsa, BeiGene has built an extensive pipeline spanning solid tumours and blood cancers, with programmes targeting PD-1, TIGIT, PARP, and other validated oncology pathways.

Manufacturing & Global Infrastructure

BeiGene operates large-scale biologics manufacturing facilities in Guangzhou and has invested significantly in end-to-end commercial infrastructure, including its own sales force in the United States and China. The company conducts clinical trials across multiple continents, with a clinical operations footprint that places it among the more active sponsors in haematology and solid tumour research globally. It has also entered into significant collaboration agreements with major pharmaceutical partners, broadening access to its pipeline assets and reinforcing its commercial reach in competitive markets.

The company's dual focus on innovation originating in China alongside regulatory approval and commercialisation in Western markets reflects a distinctive model that differentiates it from both traditional Western biopharma and purely domestic Chinese peers. BeiGene trades on Nasdaq under the ticker BGNE and on the Hong Kong Stock Exchange.

Further information is available at beigene.com.